ProCE Banner Activity

CE / CME

Advanced Urothelial Cancer: Applying New Therapeutic Options – Part 2

Podcast Episodes

In this second of 2 episodes, Arjun Balar, MD discusses the management of adverse events in patients with advanced urothelial cancer (UC) being treated with novel therapies. Listen as Rana McKay, MD, and moderator Terran Sims, MSN, ACNP-C, CCN-BC, COCN join him for case discussions and answers to audience questions.

To access episode 1, click here.

Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits

Released: February 11, 2022

Expiration: February 10, 2023

Begin Activity

Share

Faculty

Arjun Balar

Arjun Balar, MD

Associate Professor of Medicine
Division of Hematology/Oncology
NYU Langone Health
New York, New York

Rana R. McKay

Rana R. McKay, MD

Associate Professor
Department of Medicine
Divisions of Hematology/Oncology and Urology
University of California San Diego
San Diego, California

Terran W. Sims

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Acknowledgement

This program is cosupported by educational grants from Astellas and Pfizer; Bayer HealthCare Pharmaceuticals Inc.; and Seagen Inc.

This activity is supported by an educational grant from Seagen Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify the appropriate use in clinical practice of novel and emerging therapies for advanced UC

  • Describe toxicities of novel therapies for advanced UC

  • Implement strategies for the management of toxicities associates with novel therapies for UC

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech, Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Dr McKay: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, and Tempus.

Ms Sims: consulting fees: Coloplast.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

The estimated time to complete this activity is 0.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

Release date: February 10, 2022
Expiration date: February 9, 2023

Format

Podcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 9, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.